Phillip Ma
Family · Albuquerque, NMNPI 1598315772
Payments from drug & device makers
Across 121 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$300
- AbbVie$275
- AstraZeneca$203
- Novo Nordisk$140
- Nestle Healthcare Nutrition Inc.$119
- Takeda Pharmaceuticals U.S.A., Inc.$116
- plus $689 from 16 others
What the payments were for
- Food & beverage$1,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 23 | $300 |
| AbbVie | 24 | $275 |
| AstraZeneca | 12 | $203 |
| Novo Nordisk | 9 | $140 |
| Nestle Healthcare Nutrition Inc. | 7 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $116 |
| Biohaven Pharmaceuticals, Inc. | 5 | $109 |
| Merck | 6 | $94 |
| Lilly USA, LLC | 4 | $72 |
| Amarin Pharma, Inc. | 5 | $67 |
| Pfizer | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $39 |
| Boehringer Ingelheim | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Organon | 1 | $19 |
| Novartis | 1 | $19 |
| Baxter Healthcare | 1 | $14 |
How this compares
$1,842 in reported general payments places this provider in the 85th percentile of 1,080 family providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 28 | $33,334 |
| EliquisApixaban | 33 | $25,724 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $6,891 |
| Atorvastatin Calcium | 137 | $1,987 |
| Gabapentin | 144 | $1,869 |
| Levothyroxine Sodium | 136 | $1,783 |
| Amlodipine Besylate | 121 | $1,441 |
| Lisinopril | 102 | $1,426 |
| Duloxetine Hcl | 66 | $1,418 |
| Losartan Potassium | 105 | $1,397 |
| Pantoprazole Sodium | 59 | $967 |
| Metoprolol Succinate | 67 | $964 |
| Tamsulosin Hcl | 60 | $921 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $837 |
| Omeprazole | 48 | $528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $39 | $33,33428 claims |
| PfizerEliquis | $65 | $25,72433 claims |
| AstraZenecaSymbicort | $203 | $6,89130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,080 family providers in New Mexico.
Other family in Albuquerque
- Barbara FranklinAlbuquerque$28K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Charles GallegosAlbuquerque$10K
- Marlyn NewbyAlbuquerque$9K
- Annmarie FoleyAlbuquerque$8K
- Aimee CasarezAlbuquerque$7K
- Rita SuharliAlbuquerque$6K
- Matthew TotterAlbuquerque$6K
- Roberta ChampouillonAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.